Advertisement MediVector wins JPM-TMT contract to develop influenza drug - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

MediVector wins JPM-TMT contract to develop influenza drug

MediVector has secured $138.5m contract from the Department of Defense's (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) to further develop Favipiravir (T-705), that targets multiple influenza virus strains.

JPM-TMT joint project manager David Hough said the drug showed that it can mitigate flu symptoms by interfering with the influenza replication process.

In earlier animal studies and Phase 1 human clinical trials, Favipiravir has shown positive results.

The Phase 3 clinical studies of Favipiravir drug is expected to commence as early as fall 2012.

JPM-TMT facilitates the advanced development and acquisition of broad-spectrum medical countermeasures and systems to improve biodefense response capability.